You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Subset of Patients With a Very Low Risk of Dying From Melanoma
ESMO 2022: SWOG S1801 Trial of Timing of Pembrolizumab in Resected Advanced Melanoma
UV-Protective Behaviors Among American Indians and Alaskan Natives
Rapid Recommendation Update to ASCO Guideline for Systemic Treatment of Melanoma
Immunotherapy for Advanced Melanoma: A Review
Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Relatlimab and Nivolumab vs Nivolumab Alone in Untreated Advanced Melanoma